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Chapter 1 
General Introduction
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Hirschsprung disease (OMIM #142623) is a congenital malformation of 
the nervous system of the gastrointestinal tract, the Enteric Nervous 
System. The work in this thesis focuses on modes of development of 
this disease, in vitro disease modelling and possible therapeutic options. 
The Enteric Nervous System 
The gastrointestinal (GI) tract is the core of the digestive system and has 
many functions including the mixing and breaking down of ingested 
material, water and nutrient extraction and absorption, secretion of 
enzymes and propulsion of ingested material through the body for 
waste expulsion in defecation1. These functions require the input of 
various cell types communicating together in order to effectively digest 
food and avoid nutritional deficit or inflammatory responses from poor 
gut function. At birth, the GI tract, including the oesophagus, stomach, 
small intestine and colon, is approximately 3 meters in length, and 
increases to approximately 7 meters in adults3. The development of such 
an organ is complex and requires extensive elongation of the primitive 
gut tube, as well as migration of a wide variety of cell types along the 
gut, to ultimately result in co-ordinated gut activity4. Proper functioning 
of the GI system is regulated by the enteric nervous system (ENS).  
The ENS is one of the three main divisions of the autonomic nervous 
system, along with the sympathetic and parasympathetic divisions. The 
ENS is also colloquially known as the second brain or the brain in the 
gut, due to its ability to function independently from the central nervous 
system (CNS).  The basic functions of the ENS do not require input from 
the sympathetic and parasympathetic divisions, although it is influenced 
by both5. The ENS is made up of neuronal cells and supportive glial cells 
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located within ganglia, which form two distinct mesh-like plexuses in 
the wall of the GI tract (Figure 1). 
The myenteric plexus spans the entire length of the GI tract and lies 
between the longitudinal and circular muscle layers. It controls muscle 
contraction and relaxation which generates the peristaltic movement of 
the gut. The submucosal plexus, located between the circular muscle 
and mucosa, is only prominently seen in the small and large intestines. 
It regulates fluid absorption and secretion, modulates blood flow, and 
responds to stimuli from the mucosa to support gut function and 
homeostasis6. 
Figure 1. Schematic Cross-section of the adult GI tract showing the submucosal 
and myenteric plexuses either side of the circular muscle layer. Axons extend 
radially from the plexuses for communication between plexuses and into the gut 
mucosa. 
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Development of the ENS 
The ENS is derived from the neural crest which arises at the border 
between the neural plate and the non-neural ectoderm. The majority of 
cells that are fated to become the ENS originate at the level of the vagal 
neural crest. These precursor cells, known as enteric neural crest cells 
(ENCCs), migrate to the cranial end of the gut tube at week 4 of human 
development (embryonic day [E]9.5 in mice)7,8, and rapidly proliferate, 
migrate and differentiate to colonise the entire length of the gut by 
week 7 (E13.5 in mice) (Figure 2)7,8. A smaller population of neural cells 
also arises from the sacral region of the neural tube, but contributes to 
the ENS mainly in the distal hindgut9,10. In addition to the uniform 
directional (oral to anal) migration of vagal ENCCs along the gut, 
Nishiyama and colleagues showed that, in mice, ENCC migration halts 
Figure 2. Schematic of vagal neural crest cell (NCC) migration into the embryonic gut 
tube and the contribution of sacral NCCs in the hindgut. The final ganglia contain glial 
and neuronal populations.  
12
at the midgut to hindgut boundary to allow for trans-mesenteric 
migration to occur before the wave-front of ENCCs advances into the 
hindgut region11. It is unclear whether this trans-mesenteric migration 
occurs in other species, including humans, however given that 
Hirschsprung disease (HSCR) is mostly limited to the distal colon, this 
migratory path of ENCCs is interesting for further study. 
As the gut is growing and elongating during embryogenesis and foetal 
development the ENCCs are highly migratory, with cells migrating in all 
directions rather than just towards the caudal end of the gut. The 
leading wavefront of migrating cells sets the tracks for the other cells to 
follow, determining the position of the ganglionic network12,13. 
Migratory pathways are dependent on the expression of surface 
receptors in order for the cells to recognise environmental signals, if 
present. For example, GDNF, expressed in the gut mesenchyme, is 
recognised by GFRα1, expressed on the migrating NCCs and acts as a 
chemoattractant for the migrating wavefront7. Studies in avian models 
have established that migration in the pre-umbilical stage, through the 
foregut and midgut, occurs before smooth muscle formation. As the 
cells migrate along this mesenchymal gut tube, the circular muscle layer 
begins to develop, creating a different migration environment for cells 
in the hindgut10,13. Additionally, cell adhesion molecules and 
appropriate extracellular matrix (ECM) components, such as collagen 18 
and agrin proteins, secreted at the migrating wavefront, play a crucial 
role in these migratory pathways12,14. Intercellular and extracellular 
signals from surrounding cells and the ECM also influence cell fate 
decisions and components of the ECM have been studied in vitro to 
assess their effect on ENCCs and other gut cells. It has been shown that 
on tissue engineering matrices, nitrergic neuronal populations are 
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enriched with presence of collagen IV. Presence of laminin and/or 
heparan sulphate gives balanced relaxant and contractile motor neuron 
populations15.  
As cells stop migrating and find their final positions within the gut wall, 
they form connections and synapses with each other and the neural cell 
bodies group into ganglia16,17. The ENCCs differentiate into multiple 
neuronal subtypes as well as enteric glia. At least 20 enteric neuronal 
subtypes have been identified, varying in function, electrophysiology, 
neuro-transmitters and morphology18.  
Multiple trophic factors, morphogens, and transcriptional regulators 
control and influence enteric neural subtype specification within the 
ENS19. However, the mechanisms determining specific differentiation 
patterns are poorly understood and a fate map of ENCC differentiation 
does not yet exist. Factors influencing ENCC proliferation, migration or 
differentiation may alter the ratio of subtypes within the GI tract, 
depending on when and where a neuron is ‘born’ during ENS 
development, as evidenced by its exit from the cell cycle. The timing of 
cell cycle exit has been linked with lineage commitment and this could 
mean that a slowing of migration or proliferation of ENCCs would not 
similarly slow-down their differentiation and cell cycle exit20. It is 
possible that this could lead to insufficient naïve ENCCs reaching the 
distal colon. Neural activity also influences ENCC differentiation and 
migration, as treatment with neurotoxins that inhibit vesicular signalling 
has been shown to alter the ratio of neuronal subtypes and slow cell 
migration21. Thus, alterations in developmental signals can occur 
through many modes and pathways, which create opportunities for 
physiological and/or anatomical malformations of the ENS.  
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Hirschsprung Disease 
 Hirschsprung disease (HSCR) is a congenital neuropathy of the GI tract 
characterised by an absence of enteric ganglia in a variable length of 
the distal gut (Figure 3). This defect is usually confined to the colon but, 
although rare, total intestinal aganglionosis can occur. The length of the 
Figure 3. Schematic of the intestines of a healthy individual compared to a 
patient with HSCR. The tonic constriction of the distal colon in the patient leads 
to functional obstruction. The inability of faecal matter to pass causes 
inflammation and expansion of the proximal regions of the colon, observed by 
abdominal distension in the patient. 
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aganglionic segment varies from only the rectal regions, or rectal and 
sigmoid regions, (short segment), extended towards the splenic flexure 
or transverse colon (long segment), or further to the cecum (total 
colonic aganglionosis; TCA). The affected region of gut lacks intrinsic 
neural input with the result that the smooth muscles of the gut wall 
contract, causing life-threatening obstruction and preventing passage 
of stool. Complications from HSCR include infections, enterocolitis, 
abdominal swelling and potential rupture of the colon6,22-24.  
HSCR results from a failure of ENCCs to colonise the full length of the 
GI tract, which could be caused by functional deficit within the ENCCs 
themselves or in the local environment that the ENCCs encounter during 
their migration along and within the gut. The appropriate proliferation, 
migration, differentiation and survival of these cells is therefore 
essential for colonisation. The basic pathophysiological feature in HSCR 
is functional obstruction caused by the tonic contraction of smooth 
muscle of the aganglionic segment, and absence of the peristaltic 
motion of the gut. Despite extensive research, the pathophysiology of 
this is not fully understood. There is no clear explanation for the 
occurrence of tonic contraction of this smooth muscle other than the 
absence of signals from the ENS.  
Genetics of HSCR 
Genetics of Isolated HSCR 
HSCR is a congenital disorder and can be present as an isolated feature 
or part of a syndrome. Isolated HSCR has been shown to have familial 
recurrence, but it most commonly occurs sporadically2,25. The incidence 
of HSCR is estimated at 1 in 5000 live births, although this varies 
between populations6. Developmentally, HSCR has a genetic 
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component and there is a sex-linked bias in classical and short segment 
cases with a male:female ratio of approximately 4:16. To date, at least 17 
genes have been found to play a role in isolated HSCR development, in 
patients and animal models (Table 1)2,26,27. Of these, the Rearranged 
during Transfection gene (RET) has proved to be the most important. 
This can be concluded from several genetic linkage analyses which have 
shown that, even in the absence of pathogenic coding variants in RET, 
over 90% of familial HSCR is linked to the gene28,29. Mutations affecting  
Table 1. HSCR Associated genes 
Gene Location Phenotype Incidence Pathway 
RET 10q11.2 HSCR 50% familial; 
20% sporadic 
RET 
GDNF 5p13 HSCR Very rare RET 
GFRα1 10q26 HSCR Very rare RET 
NTN 19p13 HSCR Very rare RET 
PSPN 19p13 HSCR Very rare RET 
EDNRB 13q22 HSCR; WS4 3-7% Endothelin 
EDN3 20q13 HSCR; WS4 <5% Endothelin 
SOX10 22q13 HSCR; WS4 >5% Transcription factor 
L1CAM Xq28 HSCR x-linked 
hydrocephalus 
Rare - 
NRG1 8p12 HSCR 6% ERBB2; RET 
NRG3 10q23.1 HSCR - ERBB2; RET 
DENND3 8q24.3 HSCR (zebrafish) - - 
NCLN 19p13.3 HSCR (zebrafish) - - 
NUP98 11p15.4 HSCR (zebrafish) - - 
TBATA 10q22.1 HSCR (zebrafish) - - 
IHH 2q35 Hypoganglionosis 
(zebrafish) 
- Hedgehog; RET 
GLI3 7p14.1 - - Hedgehog; RET 
HSCR: Hirschsprung disease; WS4: Waardenburg-Shah syndrome. 
17
 its coding and non-coding regions have been described30,31. When 
screening for mutations, pathogenic coding variants in RET are 
identified in ~50% of familial and 15-35% of sporadic HSCR cases25,32.  
A number of loci in or around non-coding regions of RET have been 
identified, in several studies, to be linked with susceptibility to or 
protection from HSCR33-41. An enhancer variant in RET intron 1, a C>T 
SNP, was found to have a higher HSCR contribution risk than coding 
sequence variants. The frequency of the T allele in the European 
population is approximately 20% and is as high as 50% in the Chinese 
population, which could contribute to the higher incidence of HSCR in 
Asian populations25,39. Common variants in RET are well established as 
a susceptibility factor for HSCR30,42. All these studies point towards a 
central role for RET in the development of isolated HSCR and the ENS. 
RET signalling balance 
RET encodes for a receptor tyrosine kinase, RET, which is involved in 
several intracellular signalling cascades, regulating cell differentiation, 
migration, proliferation and survival. RET activation depends on binding 
with either glial cell line-derived neurotrophic factor (GDNF), neurturin 
(NRTN), artemin (ARTN) or persephin (PSPN) and with one of the four 
GDNF family receptor alphas (GFRα1-4) respectively to form a 
complex43. Disturbance of RET or any of these binding partners will in 
turn affect the action of downstream pathways, which can also disturb 
the development of other components of the peripheral and central 
nervous systems44. It has been hypothesized that, because RET proves 
to be the key player in isolated HSCR development, RET signalling is the 
fulcrum of ENS formation, with other pathways and the action of ENS-
related proteins being dependent upon correct RET expression2. This  
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Figure 4. The RET signalling balance theory proposes RET as the fulcrum of ENS 
development. Other protective or predisposing factors can contribute in varying amounts 
towards the tipping of the normal balance towards hyperganglionosis or aganglionosis2. 
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model proposes RET as the primary influencing factor in the 
multifactorial development of the ENS, the balance of which can be 
shifted by genetic or non-genetic factors to lead to a spectrum of ENS 
phenotypes, ranging from total aganglionosis to hyperganglionosis 
(Figure 4). It is likely to be a combination of (inherited) genetic and non- 
genetic factors that cause HSCR.  
Genetics of Syndromic HSCR 
HSCR occurs as an isolated phenotype with no associated anomalies in 
the majority of patients45. However, due to the genetic nature and the 
interaction of pathways in this disease it is inevitable that if ENS 
development is impaired there may be associated impairments in other 
cell types. Approximately 12% of HSCR patients have an associated 
chromosomal abnormality and 18% have additional congenital 
anomalies2,25. These associated anomalies most commonly affect other 
ectoderm or neural crest derivatives, but there are crossovers to other 
systems that may have links with cell migration or proliferation signals46. 
There are a number of defined syndromes that have HSCR as a feature 
and are generally explained by Mendelian inheritance (Table 2). In some 
of these it is a variable feature and its presence or absence may be 
influenced by modifying factors that either predispose a patient to 
HSCR or protect against its development25,46. Goldberg-Shprintzen 
syndrome (GOSHS) is caused by truncating variants in the KIF1 Binding 
Protein gene (KIF1BP)47. It is characterised by dysmorphic facial features, 
microcephaly, developmental delay, intellectual disability and short 
stature and has HSCR as a variable feature among other associated 
phenotypes. The presence or absence of HSCR in GOSHS patients is 
highly variable, even in members of the same family, with the same 
20
causative variant46,48,49. KIF1BP is associated with microtubule dynamics, 
cargo trafficking and axonal outgrowth, but its precise functions in 
development are not well known49-52. 
In chapter 3 we introduce new truncating variants in KIF1BP and add 
two patients with missense variants, one with classical GOSHS features 
and the other with an alternative phenotype. Functional studies of the 
missense variants indicate that a threshold of KIF1BP expression is 
necessary to avoid GOSHS development. 
Table 2. Characterised syndromes with HSCR as a mandatory or frequent feature. 
Syndrome Gene(s) HSCR Other features 
WS4 SOX10; 
EDNRB; 
EDN3 
100% Pigmentary anomalies; sensorineural deafness 
MWS ZEB2 
GOSHS KIF1BP >70% Craniofacial dysmorphia; microcephaly; 
polymicrogyria; developmental delay 
DS Tri21 ~7% Characteristic facial dysmorphism; intellectual 
disability; developmental delay 
CCHS PHOX2B ~20% Autonomic respiratory failure 
BBS Several Pigmentary anomalies; renal anomalies; 
intellectual disability; polydactyly 
MKKS MKKS/BBS6 ~10% Cardiac anomalies; polydactyly; 
hydrometrocolpos 
SLOS DHCR7 - Developmental delay; intellectual disability;
microcephaly; craniofacial dysmorphism;
syndactyly
CHHS RMRP ~10% Metaphysial dysplasia; dwarfism; fine, sparse,
blonde hair; anaemia; immunodeficiency
MEN2 RET ~2% MTC; parathyroid tumours; pheochromocytoma
HSCR: Hirschsprung disease; WS4: Waardenburg-Shah syndrome; CCHS: Congenital 
Central Hypoventilation Syndrome; MWS: Mowat-Wilson Syndrome; GOSHS: Goldberg-
Shprintzen Syndrome; BBS: Bardet-Biedl Syndrome; MKKS: McKusick-Kauffman Syndrome; 
SLOS: Smith-Lemli-Opitz Syndrome; CHHS: Cartilage-Hair Hypoplasia Syndrome; MTC: 
Medullary Thyroid Cancer. 
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Copy Number Variation in HSCR 
As well as defined monogenic syndromes, there are many patients with 
complex phenotypes and multiple associated developmental defects 
that are yet unexplained. Chromosomal abnormalities may explain part 
of these clinically complex patients. Changes in the number of copies of 
DNA present in the genome are termed Copy Number Variations 
(CNVs). These can contribute to phenotypes, diseases or syndromes that 
are influenced by gene dosage53. CNV is also known to contribute to 
HSCR disease aetiology. Chromosomal band deletions54,55 and 
duplications54,56-58 have been described in HSCR patients, most of these 
being syndromic patients. Deletions of chromosomes 10 and 13 were 
instrumental in the identification of RET and EDNRB as major HSCR 
genes25,59. Patients with Down Syndrome, trisomy 21, have a 100 times 
higher incidence of HSCR than the general population25, implying that 
genes or regions on chromosome 21 are sensitive to dose increase and 
may increase susceptibility to ENS disorders. Large CNVs are more 
frequent in individuals with developmental anomalies compared to 
healthy controls60. In addition, more common CN polymorphisms 
(CNPs) are thought to be modifiers of the HSCR phenotype61,62. 
Therefore, we believe that rare CNVs could contribute significantly to 
syndromic patients with HSCR as a feature, where no pathogenic variant 
can be identified. In chapter 4 this phenomenon is explored in HSCR 
patients with and without other congenital anomalies in order to find 
new genes or regions that may be causative for the HSCR phenotype. 
Other factors in HSCR development 
Known HSCR genes have only been implicated in ~30% of cases25. There 
has been no implicated high penetrant causative variant found in the 
remaining ~70% of cases and in sporadic, non-familial, HSCR genetic 
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counselling is challenging. There are a number of possible reasons for 
the missing heritability. There may be an epigenetic component 
affecting protein expression of the known, implicated pathways, or 
there may be other genes involved in pathways up or downstream of, 
or otherwise linked to, these pathways that have not yet been 
elucidated. Changes in expression of HSCR related genes, either due to 
variation in methylation regulating genes, or methylation changes to 
promotor or enhancer regions themselves, have been shown to 
influence ENS development63-65. Environmental factors including 
maternal diet and use of prescribed drugs can also play a role and may 
influence epigenetic patterns. This is most likely limited to being a small 
influencing factor rather than being significant enough alone to cause 
any damaging phenotype66-69. 
A further theory that warrants investigation is the existence of somatic 
cell variations affecting a subset of cells important in the ENS 
colonisation of the GI tract. During the accelerated cell division and 
growth of embryonic development there are many chances for mistakes 
to be made in DNA replication. If there is a failure of DNA repair 
mechanisms to identify and correct these mistakes this would lead to 
subsets of cells containing variants that are not present in the remaining 
embryonic cells. Dependent on the temporal and spatial identity of a 
cell in which this variation occurs this may lead to a whole system, organ 
or tissue containing a mosaic variant. However, as discussed in chapter 
2, such defects would prove difficult to identify in patient material. 
Diagnosis & Treatment 
HSCR is suspected when a newborn infant fails to pass meconium within 
the first 48 hours of life, which is generally the case for >90% of HSCR 
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cases22. Patients are usually diagnosed before 3 months of age, 
although some within the first year or upon weaning from breastmilk. 
Rarely, an older patient will be diagnosed, but they generally have a 
history of chronic obstipation and the aganglionic segment is short22. 
When HSCR is suspected, the diagnosis is usually confirmed by taking a 
rectal suction biopsy. The length of the aganglionosis is established 
using histological examination for presence/absence of enteric ganglia. 
The current standard of care for HSCR is surgical removal of the affected 
aganglionic region and anastomosis of the ganglionic bowel region to 
the anus. A colostomy may be fashioned prior to surgery. This allows 
the obstruction to be bypassed, and allows the gut to grow and 
inflammation to diminish. The most common surgical mode for 
resection is transanal endorectal pull-through (TEPT), which minimises 
the invasive nature of the surgery as the abdominal cavity does not need 
to be opened. TEPT can take place entirely transanally. However, it is 
commonly performed in combination with laparoscopy or laparotomy, 
to visualise and mobilise the colon abdominally70. Common surgical 
procedures are the Swenson, Soave, Duhamel and Rehbein procedures 
which are adaptations of similar pull-through approaches with 
differences in anastomosis6,70,71. 
Although surgical intervention is generally effective in preventing 
obstruction, it may not prevent further complications for the patient, 
including enterocolitis, faecal incontinence or chronic constipation, and 
an increased risk of infections23,72,73. TEPT may avoid some of the risks 
of open abdominal surgery, however the rates of faecal incontinence as 
well as the psychological and psychosexual side-effects of this surgery 
may negatively impact on the quality of life of HSCR patients24,72,74,75. It 
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has also been shown that TEPT can cause long-term damage to the anal 
sphincter, due to the prolonged and significant period of being 
stretched. This can be minimised if a combined laparotomy technique 
is implemented6. If complications arise following surgery, it may be 
necessary to have a redo surgery. A redo surgery is primarily for patients 
with persistent constipation and may involve removal of a further 
section of colonic tissue to ensure that the transition zone between the 
ganglionic and aganglionic regions is totally removed, as this is likely to 
have disturbed function and may have been inaccurately identified at 
the time of surgery76. Correction may also be necessary if there is a 
twisting of the bowel in the anastomosis which leads to discomfort or 
abdominal pain77. Patients who undergo corrective transanal surgery 
have a higher risk of damage to the anal sphincter, so this is only 
undertaken if the benefits outweigh this risk. 
Additional, non-surgical, treatment options for HSCR include continued 
use of a colostomy, modified diet, laxatives and/or anti-diarrhoeal 
drugs, electrical nerve stimulation, hospital visits for rectal/colonic 
irrigation and injection of bulking agents to thicken the anal sphincter. 
These options, as well as the above-mentioned surgeries, leave a lot to 
be desired in terms of patient care. Quality of life can be negatively 
affected and, while paediatric patients are resilient to some 
psychological impacts, their frequent hospital visits and the social 
implications of faecal incontinence could complicate educational and 
social commitments in later life24,72,75. Due to normal life expectancy in 
HSCR patients the need for prolonged treatment can generate large 
healthcare costs78-81. New treatment avenues that are being explored in 
the field include nerve cell-replacement or transplantation therapies, 
discussed here and in chapter 5. Other, less well explored options can 
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be multidisciplinary and effective for a greater range of patients, as 
discussed in chapter 6. 
Cell-based therapies for HSCR 
One of the major drives in ENS translational research is to develop a cell 
replacement therapy for enteric neuropathies such as HSCR. HSCR is the 
primary focus for cell replacement therapy as cells could be 
transplanted into the aganglionic region in an attempt replenish and 
rescue the absent ENS. There are a number of cell types that are 
generally considered for any cell transplantation therapy: cells that are 
obtained from the same tissue as the cells that are to be replaced; 
ameliorative cells, such as mesenchymal stem cells (MSCs), that facilitate 
natural recovery within the body and decrease inflammation; or stem 
cells, either of embryonic, postnatal or reprogrammed origin, that are 
differentiated towards the desired cell lineage or type.  
Sources of cells for ENS therapy 
A number of options for a viable cell source for transplantation 
therapies have been explored82-86. The discovery of ENS stem cells that 
persist within the postnatal gut, and the assessment of their proliferative 
potential in mice13,87, led to multiple attempts to isolate them from 
human colon and characterise them in vitro88. Although they provide an 
ideal cell source for functionally investigating the ENS, their proliferative 
capacity may be inadequate for generating required numbers of cells, 
especially when obtained from postnatal gut89. Current culture methods 
of ENCCs in neurospheres maintain a progenitor state in some cells, and 
these cells are able to integrate and form a functional network upon 
transplantation85,90-92. However, the area covered remains low in mouse 
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models and considering the scale-up to human gut, it is likely that many 
more cells would be required in a human therapy.  
Pluripotent stem cells (PSCs) were initially thought to be ideal stem cell 
source for treating a variety of diseases. First studied from embryonic 
origin, embryonic stem cells (ESCs) offered a potentially unlimited 
source of cells to study differentiation pathways93,94. However, ethical 
considerations of using human embryos for this purpose, as well as the 
need for immunosuppression in transplantation, created significant 
barriers for their use95. The generation of induced PSCs (iPSCs) from 
human fibroblast cells by Takahashi and Yamanaka in 2006 led to a huge 
advance in developmental biology research. These cells have 
comparable differentiation potential to ESCs and can be created with 
somatic cells from the intended patient, circumventing source and 
immune rejection issues96,97. 
However, persisting issues include the genomic stability of the iPSCs, 
which have been shown to accumulate chromosomal aberrations after 
a number of passages in culture, and the ability to differentiate the cells 
into the correct lineage whilst avoiding the introduction of tumorigenic 
cells to a patient98-100. An additional consideration when thinking of a 
transplantation therapy for a genetic disease, is the genetic background 
of the patient and whether the cells’ function will be negatively affected 
by the pathogenic variant that initially caused the disease. 
A number of protocols have been developed for the differentiation of 
PSCs towards an ENS lineage101-104. Most of them initially achieve a vagal 
neural crest expression pattern and the study from Fattahi, et al., shows 
promise in transplantation and rescue of a mouse model of HSCR103. 
However, if iPSC-derived neural crest cells (NCCs) are to be used for 
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disease modelling and transplantation, a standardised method for 
creation and characterisation should be developed to ensure 
replicability. Particularly in the case of using HSCR patient derived iPSC-
NCCs for genetic characterisation, standardised and controlled methods 
would ensure that any differences measured are due to genetic 
background rather than protocol variation. The parameters for 
measuring cell function, to assess the need for genetic correction, as 
well as the necessary stage of differentiation for ideal integration 
efficiency following transplantation, remain to be determined105. 
Aims & Outline of this Thesis 
The aims of the work described in this thesis were to investigate the 
missing heritability that is seen in HSCR in both isolated and syndromic 
cases, understand more about the development and differentiation of 
ENCCs, assess suitability of various cell sources for transplantation 
therapy, and explore possible treatment avenues for current and future 
HSCR patients. 
The possibilities of somatic variants contributing to the development of, 
and accounting for the missing heritability in, HSCR are discussed in 
chapters 2.1 and 2.2. In chapter 2.1 we outline the need for appropriate 
distinction between inherited parental mosaicism and true somatic 
mosaicism, proposing an appropriate experimental design to truly 
differentiate between the two in HSCR patient tissue. In chapter 2.2 this 
experimental design is utilised to look for ENCC specific variation in 
patient tissue. We further discuss the mechanisms of somatic variation 
in ENCCs and why, due to the developmental patterning of the ENS, 
they are unlikely to be detected, even if they have contributed to the 
phenotype. 
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In syndromic cases, HSCR can be a variable feature, the presence of 
common RET variants as well as the type of causative variant may 
influence HSCR development. The presence of HSCR in cases of GOSHS 
is discussed in chapter 3. Pathogenic variants in KIF1BP lead to GOSHS, 
in which HSCR is a variable feature. Given that HSCR is not a mandatory 
feature, it is likely that predisposing factors can be found to have 
involvement in its development. A number of patients have been 
reported in the literature, and truncating variants in KIF1BP have been 
found to be causative in all sequenced cases. In this chapter, we report 
nine new patients with KIF1BP variants, and functionally investigate, for 
the first time, three new missense variants identified in two patients with 
differing phenotypes. We also look at the presence of RET common 
SNPs, as a determining factor for the presence or absence of HSCR.  
Another possible genetic factor for HSCR in syndromic cases is the 
presence of CNVs that affect dosage sensitive HSCR loci. In chapter 4 
we compare the size and number of CNVs between syndromic and non-
syndromic HSCR cases, to find new candidate genes/loci.  
To further look into the underlying pathogenesis of HSCR development 
we created iPSC lines from four patients with different pathogenic 
variations. These cells offer possibilities for disease modelling, 
functional investigation of variants as well opening the door to future 
iPSC-enteric neuron transplantation options. In chapter 5 we present 
the characterisation of these patient-derived iPSCs and explore 
variations in their function compared to iPSCs generated from healthy 
controls. We also discuss their genomic stability and viability with a view 
to their use in cell therapy. 
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In order to bring an expedient option for the treatment of HSCR patients 
who continue to suffer from gastrointestinal problems following the 
current surgical standard of care, we may have to think beyond 
biological interventions. The technological world has arguably been 
able to advance at a faster rate than the development of purely 
biological treatment options. With the advances in microelectronics and 
prosthetic technologies incorporating sensory input, the opportunities 
for developing transplantable devices may provide a more elegant 
solution than the more primitive prostheses currently available. These 
ideas are discussed in chapter 6, together with a patent proposal for an 
artificial prosthetic sphincter with an anatomically relevant mechanism 
and design which could provide therapeutic options for HSCR patients, 
but also to others suffering from faecal incontinence, or loss of anal 
sphincter control. 
Chapter 7 summarises the work in this thesis and discusses future 
prospects in the field of ENS development, as well as possibilities for 
treating patients with HSCR and related disorders. 
All supplementary material can be found here.
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Chapter 2.1 
Do RET somatic mutations play a role in 
Hirschsprung disease? 
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Dear Editor, 
We have read the manuscript from Jiang et al.,1 recently published in 
your journal, with great interest. In this, a contribution of RET somatic 
mutations for Hirschsprung disease (HSCR) is hypothesized. 
HSCR is a complex inherited disorder characterized by the absence of 
enteric ganglia in the distal part of the colon. Several genes and loci 
have been described to underlie disease pathogenesis. However, 
variants in these genes explain no more than 20% of all cases2. This 
missing heritability seen in HSCR is a common feature of many 
complex disorders and explaining it remains challenging. Considering 
that HSCR develops during embryogenesis as a result of either 
impaired migration, proliferation or differentiation of enteric neural 
crest cells (ENCCs), it is tempting to consider that somatic mutations 
occurring during the development of the enteric nervous system, and 
specifically affecting ENCCs, can also contribute to HSCR genetics. 
Jiang and colleagues think that this is possible, and we share the same 
opinion, as we believe that somatic variants could be underrecognized 
in HSCR, and thus, possibly account for some of the missing 
heritability. However, the results described by the authors do not, in 
our opinion, fully support the conclusions of the manuscript. This is 
mainly because routine genetic testing on DNA derived from blood or 
saliva would not find these ENCC specific mutations, nor would easily 
detect low mosaic variants. With this letter, we intend to further 
discuss our concerns and highlight the difference between causative 
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somatic mutations and germline mosaicism resulting in seemingly de 
novo mutations in the next of kin. 
In their study, the authors screened 152 HSCR patients by targeted 
exome sequencing and direct gene screening. In eight patients they 
identified putative deleterious de novo variants in RET. Since RET is the 
major HSCR causing gene,3 they assumed that these variants were 
responsible for the disease phenotype. However, only six patients 
carried a truly de novo RET mutation, as in the other two the variants 
identified were also found in one of the parents. The authors 
continued the genetic analysis of the six remaining patients, and 
described based on their findings, that the RET mutations identified 
were somatic. This result led to the conclusion that RET somatic 
mosaicism is present in 75% of the HSCR cases and is, therefore, 
underrecognized. However, in four of the six patients studied, 
germline mosaicism was identified in the parents. As these variants are 
transmitted to the affected next of kin as heterozygous variants, these 
cannot represent somatic mosaicism. In addition, the parents are not 
affected, leading us to speculate that their ENCCs are either not 
affected by the mutation or that the mutational load in their ENCCs 
does not cross a threshold for abnormal ENS development. Therefore, 
although these four families are likely to represent germline mosaicism 
resulting in seemingly de novo mutations in the next of kin, they do 
not support the conclusion that RET somatic mutations are 
underrecognized. These heterozygous mutations would be detected 
(and are detected in these patients) in routine genetic screening and 
as such, do not resolve missing heritability due to “recognizing” 
somatic mosaicism. 
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For the remaining two patients, the RET variants identified were 
present in blood, saliva, and colon, in family 1 (39/39/44%) and family 
2 (44/35/39%). The authors validated the sequencing data with TA 
cloning, but the results are variable even within the same tissue, and 
the differences seen in the amplicon-based sequencing test are well 
within the normal range for detection of a heterozygous variant. 
Moreover, the samples tested—blood, saliva, and colon—derive from 
tissues originating from different germ layers. Blood, mostly 
lymphocytes, is derived from mesoderm; saliva, lymphocytes, and 
epithelial lining of the mouth are derived from mesoderm and 
ectoderm; and the colon has contributions from all three germ layers. 
The high allele frequencies identified in all three samples for both 
patients (>30%) does not allow for discrimination between very early 
developmental stage somatic mutations or de novo variants present as 
a germ-line mosaicism in one of the parents. Although the authors 
acknowledge this fact in the discussion, it is more fitting to conclude 
that the variants identified in these two remaining patients are likely to 
be de novo heterozygous variants.  
In conclusion, we agree with the hypothesis of Jiang et al. and think 
that somatic variants might well play a role in HSCR development. 
However, based on the results presented we think that it is not 
possible to make such a conclusion, as no true somatic RET mutations 
were identified in any of the presented patients. We believe that to 
draw the conclusions stated, the allele frequency of the mutations in 
ENCCs, surface ectoderm, and, for instance, blood or fibroblasts would 
need to be compared because these represent different germ layers 
and include the cells involved in HSCR. An experimental setup that 
would isolate cells specifically from each germ layer, as well as ENCCs, 
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or that would separate the colon into various cell types, would be 
necessary to determine whether true somatic mutations impact HSCR 
development. Only if differences were found under such conditions 
could the authors show that RET somatic mutations are indeed 
underrecognized in HSCR.  
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Chapter 7 
General Discussion
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Hirschsprung disease (HSCR) is a rare congenital malformation of the 
enteric nervous system (ENS) characterised by an aganglionosis in a 
variable length of the distal gastrointestinal (GI) tract. Aganglionosis 
results in constriction of the smooth muscle in the affected region, 
leading to a functional obstruction1. During development, the cells that 
form the ENS bud from the neural crest and rapidly proliferate and 
migrate along the developing gut tube. These neural crest cells (NCCs) 
eventually form the enteric ganglia and differentiate into neuronal 
subtypes and glial cells located in the submucosal and myenteric 
plexuses of the ENS. A disturbance to proliferative, migratory, 
differentiative and/or survival functions in these cells could contribute 
to the pathogenesis of HSCR2. The current treatment for HSCR consists 
of surgical resection of the affected gut region, however most patients 
continue to have prolonged GI tract complications following surgery3,4. 
Understanding the development and pathogenesis of HSCR is vital to 
provide improved treatment options for these patients. 
Factors involved in the development of HSCR 
The disruption of ENS development is thought to be broadly under 
genetic control. A number of key NCC regulating genes have been 
implicated in HSCR pathogenesis. However, pathogenic variants in 
these genes only explain ~50% of HSCR cases2. It is therefore likely that 
other strong pathogenic variants in yet unknown genes, and/or 
combinations of pathogenic variants and weaker modifying variants, 
contribute to the aetiology and pathogenesis of HSCR5. Of the genes 
known to be involved in HSCR pathology, RET is understood to be the 
major influencer, acting as a fulcrum in the balance between 
aganglionosis and hyperganglionosis5. If there is a strong RET or other 
causal variant then the presence or absence of risk alleles6-8 at common 
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SNP locations is unlikely to influence disease development substantially. 
The RET balance is therefore more representative in cases where a 
combination of variants and other risk factors have the cumulative effect 
of a HSCR phenotype.  
If a patient presents with a multi-feature syndromic form of HSCR then 
the risk alleles may slightly influence presence or absence of HSCR, but 
more likely large copy number variations and chromosomal 
displacement affect its presence or absence. It could also be that 
combinations of missense variants and modifying SNPs have a 
cumulative influence on pathology in both non-syndromic and 
syndromic forms of HSCR. 
Genetics of isolated HSCR 
In non-syndromic isolated HSCR cases RET is the major genetic risk 
factor. However, the inheritance in sporadic non-syndromic HSCR cases 
is considered complex2. In this group, many genes other than RET have 
been identified. The identified genes are primarily involved in either the 
RET signalling pathway or the endothelin signalling pathway, and it is 
likely that other up- or down-stream influencers of these are yet to be 
identified. Due to the frequency of sporadic isolated cases and the 
unexplained genetic origin in many familial cases, it can be safely 
assumed that there are further disease genes yet to be identified, and/or 
factors other than the genomic DNA sequence of a patient that may 
play a role in disease pathogenesis9,10. Susceptibility to HSCR could be 
further influenced by stochastic effects on gene expression, additional 
variants in other genes that influence regulatory elements, and 
environmental effects on gene expression6. Additionally, the effects of 
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variants may be subject to epigenetic factors and changes in 
methylation patterns, which could also affect the complex heritability.  
Genetics of unexplained syndromic HSCR 
Approximately 12% of HSCR cases are associated with chromosomal 
anomalies, and approximately 18% of cases present in combination with 
other defects or features11. In contrast to non-syndromic HSCR, in 
syndromic HSCR we assumed that large copy number variations (CNVs) 
could explain part of the missing heritability. In chapter 3 we discuss 
CNV and how large CNVs may influence HSCR pathology if they overlap 
dose-sensitive genes that affect ENS development. HSCR can present as 
one symptom in patients with multiple associated anomalies, these can 
be recognised syndromes or newly presenting multi-feature 
presentations11,12. In multi-feature patients with known strong 
pathogenic variants CNVs have little influence on HSCR development. 
We demonstrate that CNVs in multi-feature patients, without a known 
pathogenic variant, tend to be longer and affect regions that contain 
genes expressed in the developing ENS. This data needs to be replicated 
in independent cohorts to confirm if candidate genes within large CNVs 
are seen in multiple patients. Investigations in zebrafish models, to 
knock down these genes or express multiple copies, may help to 
confirm new candidate genes present within CN loss/gain regions.  
Missense variations in known syndromic HSCR 
Missense variants can go unnoticed and be present in the healthy 
population, but still disturb protein folding, binding or other functions. 
They can have the same pathogenicity as a loss of function variant, 
specifically in recessive diseases in which carriership does not result in a 
disease phenotype. In chapter 4 the identification of missense variants 
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in Goldberg-Shprintzen syndrome (GOSHS), as well as the presence or 
absence of HSCR as a variable clinical feature in GOSHS is discussed. 
Truncating variants in the KIF1 binding protein gene (KIF1BP) are known 
to cause GOSHS13. The presentation of two patients with missense 
variants in KIF1BP was interesting given the lack of knowledge of protein 
folding and interactions. There is no crystal structure available of KIF1BP 
and the interactive sites are not well understood. Given that loss-of-
function variants have been reported in all 7 exons, it is likely that there 
are many regions, even in the terminal regions of exon 7 that are vital 
to RNA or protein stability. The two patients presented with different 
phenotypes and the finding of missense KIF1BP variants in patient NL1 
was surprising, given their clinical presentation. The homozygosity of 
the missense variant in patient CYP3, or the region affected, may have 
been a tipping factor in the development of classical GOSHS with HSCR. 
The expression of KIF1BP in CYP3 is lower than in NL1, despite the 
compound heterozygous variants in exons 1 and 7. A CNV analysis in 
these patients, particularly patient NL1, may be informative to 
determine if there are other candidate regions that have influenced 
neural development. As no other pathogenic variant was identified in 
diagnostic screening of patient NL1, and given their syndromic features, 
it may be that CNV of dose dependent genes contributes to their 
neurological phenotypes. This is the case in HSCR patients with 
associated syndromic features and would be interesting to investigate 
in other multi-feature patients.  
Missing heritability in HSCR 
As previously mentioned, in many HSCR cases a genetic cause for the 
disease cannot yet be identified. This can be partly explained by the 
complexity of inheritance patterns, presence of low-penetrant non-
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coding variants and the influence of risk alleles14. In chapter 2 we 
discussed somatic mosaicism as an influencer of HSCR, and the difficulty 
of identifying this phenomenon in relation to a HSCR phenotype. The 
developmental patterning of the ENS is such that a variant originating 
early has a high chance of being out-competed by other “healthy” 
cells. Unless this somatic variant gives a competitive advantage, such as 
higher proliferation or migration rate. This could lead to these cells 
reaching the distal colon and being unable to differentiate to the correct 
lineages and/or survive. We conclude that it is therefore extremely 
difficult to prove that true somatic variants contribute to HSCR 
aetiology, but it cannot totally be ruled out as a mode of missing 
heritability or a cause of some sporadic cases. 
As somatic mutations appear unlikely to play a major role in HSCR, the 
question of what might explain these unsolved cases remains. A 
possible problem could be the genes that are selected as being 
candidates for HSCR. Current filtering criteria selects genes that have a 
clear role in neuronal development, are expressed in the developing 
central nervous system (CNS) or ENS, or expressed in NCCs15. It can be 
assumed that there are HSCR causing variants that are not expressed in 
ENCCs themselves, but in other developing GI tract tissues. Variants in 
genes expressed in smooth muscle or connective tissue could change 
the local gut environment through which ENCCs migrate16. These 
changes could leave the distal colonic segment unable to support the 
migration, incorporation or survival of the ENCCs, an example of this is 
variation in EDN317,18.  
Moreover, the timing of cell-cycle exit has been shown to be of 
importance to ENS subtype specification19, the current filtering criteria 
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could also exclude cell cycle genes that may influence ENS 
differentiation. In order to fully understand the enteric neural subtypes 
derived from ENCCs it would be beneficial to utilise single-cell RNA 
sequencing technologies to build a control database from healthy gut 
at various developmental stages as well as postnatally. This could be 
built of the ENS as well as other GI tract cell types. Once a baseline of 
expression at various points along the GI tract is established then 
comparisons can be made with different disease states. This could also 
help with the identification of causal genes and further understand links 
in the developmental pathways that are disrupted in HSCR 
development. 
Non-genetic influencing factors 
Other than inherited and somatic alterations, external factors can also 
influence ENS development by changing the epigenetic landscape9,20. 
Using a similar strategy to that mentioned above, it would be beneficial 
to create a control database for the methylation state of various regions 
and developmental stages of the GI tract. Initial efforts could focus on 
isolation of ENCCs from control gut in order to establish methylation 
patterns of the ENS. Eventually other cell types and full gut sections 
could be included to be able to compare HSCR patient tissue and find 
large methylation changes. The creation of expression maps of the ENS, 
both with RNA and methylation patterns, would be pivotal to linking 
known pathways together and finding new players in the network of 
ENS development. 
The ability of clinical geneticists to give reliable genetic counselling to 
the families of patients relies on an understanding of the heritability of 
the condition. This is dependent on a knowledge of the genetic 
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background of HSCR pathogenesis as well as the non-genetic 
influencing factors. However, it may not be possible to explore every 
avenue, and there will still be sporadic cases that are difficult to explain. 
Modelling HSCR 
Proliferation, migration, differentiation and survival of ENCCs is a major 
focus of research and deviations of these processes are shown to cause 
aganglionosis in animal models of HSCR21. There are cases where the 
causative variant is known to be disruptive in these mechanisms and is 
shown to have expression in ENCCs specifically. However, for many 
patients the remaining ganglionic gut functions to a manageable 
degree and no other physiological problems are reported other than 
malfunction of the anal sphincter region. Animal models for 
developmental disease can only truly be useful if the genetic variant is 
known, and there is a practical limit to the number of genes that can be 
investigated in one model. The use of patient-specific cells to create a 
model circumvents this issue as the genetic background does not need 
to be fully known to functionally test for defects. 
In chapter 5 the creation of induced pluripotent stem cells (iPSCs) from 
HSCR patients was presented. These iPSC lines each harbour variants for 
known causative HSCR genes and were investigated for differences in 
function that may influence their ability to rescue the ENS using cell 
transplantation strategies. These iPSCs could also be utilised for disease 
modelling at the cellular level. 
The development of a reliable in vitro model for HSCR might help to 
dissect small cellular changes in ENCCs and/or the local gut 
environment. A 3D organ-on-chip system for GI tract development and 
function would be ideal to investigate the interplay of the different cell-
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types in the gut that are necessary for normal ENS development. Initial 
establishment of such a system with iPSC lines from healthy controls will 
allow the optimisation of cell-type ratios and flow of nutrients. Such a 
model, and generation of iPSCs from patients, will allow for the 
investigation of individual patient gut and help to determine the 
functions that may be disrupted during development. Moreover, it will 
also be help to determine whether ENCCs, smooth muscle, mucosal 
interaction or extracellular matrix (ECM) components were altered. 
Although gut organoids also offer a method of creating a 3D gut-like 
environment for cell transplantations, the spheroid structure is random 
which will influence intercellular signalling22. Gut organoids form a self-
organising lumen system which creates multiple signalling gradients 
that are difficult to compare between organoids. An organ-on-chip 
system would offer a more organised and replicable model and is 
already being used with mucosal models to create an epithelial layer 
that can support a microbiota23. 
Cell transplantation therapy 
As discussed in chapter 5, the possibilities for cell replacement therapy 
in HSCR have been explored for a number of years. The ability of 
transplanted cells to find the appropriate positioning, into either 
submucosal or myenteric plexus, and to form functional connections, 
both with other transplanted cells and with target cells within the gut, 
is vital to transplantation success. The appropriate cell type for this 
purpose, and an optimal transplantation strategy still need to be 
determined when scaling up from mouse to human gut24. No human 
trials have yet been attempted, but initial transplants into HSCR mouse 
models have been encouraging. Both injection of postnatal enteric 
neural crest cells (ENCCs)25,26 and of more proliferative pluripotent stem 
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cells (PSCs) differentiated towards neural crest27 have shown an 
integration and spread of transplanted cells.  
Initial transplantation studies established the potential of postnatally 
derived ENCCs to integrate and survive in explanted colonic 
segments28,29. In vivo transplantation of ENCCs of embryonic and 
postnatal origin has been shown to lead to the engraftment of donor-
derived cells within recipient colon25,30. Additionally, it was shown that 
ENCC-derived neurons adopt the appropriate localisation within the gut 
and can give rise to various enteric neurons, including the main 
subtypes for excitation (ChAT, VAChT, Calretinin and Calbin-din) and 
relaxation (nNOS and VIP)25,30. The transplanted cellular networks were 
also shown to closely localise with the endogenous ENS, suggesting 
functional integration of the transplanted neurons 
Methods of transplantation 
Current protocols for transplantation of cells into in vivo gut involves 
injection of cells in suspension with saline or matrigel26,27. Injection of 
ENCCs has proven safe in longer term follow-up and no migration of 
cells to ectopic sites was observed. Using PSCs, it is uncertain how many 
of the injected cells remain at the injection site and which other 
locations cells may reach. It is a recognised pattern following injection 
of PSCs to other organs that, although beneficial effects may be seen in 
the target tissue, cells are found in other organs31. It is also likely that 
many injected cells will die before making cell-cell contact32. Therefore, 
the already high numbers of cells required with this method, given the 
size of the target organ, may be even higher than anticipated when 
accounting for cell viability. Cellular scaffolds, injectable gels or other 
devices may make the environment more amenable to cell invasion, 
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lead to easier introduction of the cells, increase cell survival and avoid 
the migration of cells beyond the desired location33,34. 
Over-invasion and mass migration and proliferation is a known issue in 
PSC transplantation31. The study by Fattahi et al., considered as a 
landmark paper, shows transplantation of PSC-derived NCCs to wild-
type and Ednrb-/- mouse models27. The study shows a promising start to 
integration of PSC-derived NCCs and migration of transplanted cells 
along the GI tract. However, it has yet to be determined whether these 
cells also migrate to other regions in the body, especially connecting 
abdominal organs and this was not investigated with the reported 
transplantations. The extensive migration that they present is contrary 
to ENCC transplants reported in literature, which show a more modest 
migration to form small ENS-like plexuses in mouse gut25,26,28,30,35,36. The 
interesting factor in these studies is how many injection sites would be 
necessary in the human gut in order to effectively form a functional ENS. 
The highly proliferative nature of the PSC-derived cells could circumvent 
this, although it is vital to ensure that all transplanted cells are 
adequately differentiated to at least a multi-potent single germ lineage 
progenitor state as opposed to retaining ability to form other lineages. 
The slowing of the cell cycle to a point of normal turnover for tissue 
maintenance is required after the desired integration of cells, otherwise 
the tumour-risk from the transplanted cells is higher37.  
Numbers matter 
It has been shown that in development critical threshold numbers of 
NCCs are required for full colonisation of the GI tract38. It is also known 
that cells benefit in culture from contact with other cells producing 
“friendly cytokines”39. A similar phenomenon may translate in 
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transplantation where both adequate cell number and density are vital 
to transplantation success. A disadvantage of the significant cell 
expansion needed to create large numbers of cells is the propensity of 
cells to acquire genetic and epigenetic changes upon long-term culture 
and expansion40-42. Such changes may reduce the efficacy of generating 
specific cell derivatives, or could potentially compromise safety, for 
example by promoting tumour growth. ENCCs offer less tumorigenic 
risk than pluripotent alternatives37, and a more primed ability to form 
these enteric neural subtypes directly25. However, they may not be 
proliferative enough for expansion to required numbers43. Current 
culture methods do not generate enough cells for both characterisation 
and transplantation. Pluripotent cell types expand more quickly in 
culture than postnatal stem cells, which would decrease expansion time 
for generating sufficient numbers. 
Safety of Cell Transplantation 
Human PSCs are becoming more popular as a therapeutic tool and are 
currently being investigated in clinical trials for a number of conditions, 
including macular degeneration, spinal cord injury, diabetes, heart 
disease and Parkinson’s disease44. However, before these cells can safely 
be used in routine therapies, a better understanding of their behaviour, 
and understanding the possible genetic changes that may have 
occurred during their processing, is required.  
Safety discussions to date have focused mainly on possibility of 
teratoma formation from transplanted cells, migration of cells beyond 
the tissue of interest and the occurrence of genetic variation arising 
during cell culture. To mitigate the possibility of teratoma development 
from transplanted cells the appropriate differentiation stage would 
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need to be reached. Cell therapy should consist of administering 
progenitors or differentiated derivatives rather than undifferentiated 
stem cells, and the accidental transplantation of undifferentiated cells 
should be avoided37. With the appropriate checks and characterisation 
of cells the chance of teratomas would be minimal. Another safety issue 
is the spread of the transplanted cells outside the tissue of interest, as 
discussed briefly above. When cells integrate into non-target tissues, 
possibly in combination with (epi)genetic changes, this could have 
profound consequences31. Monitoring the spread of cells is therefore 
crucial and the investigation into methods to ensure that transplanted 
cells remain at the transplantation site is necessary.  
The primary focus of attention should be on the potential (epi)genetic 
changes that may have arisen during creation and culture of PSCs. It is 
these somatic (epi)genetic changes that may have a substantial impact 
on the behaviour of the PSCs and may even lead to malignant 
transformation of the mutated cells45. Monitoring the PSCs for such 
genetic changes is therefore crucial. Discussions are still ongoing on 
how to screen cells and how to interpret the results in order to evaluate 
their significance for the safety of therapeutic applications46. Due to the 
risks associated with significant cell expansion in vitro, the time in 
culture and number of passages of cells should be kept as low as 
possible. Cells should be checked genetically, preferably by exome 
sequencing, before use. As long as the effects of individual genetic 
variants on the PSCs or differentiated cell types are uncertain, and while 
cells are likely to spread from the target tissue, the introduction of a 
conditional suicide gene could provide a fail-safe strategy for 
eliminating cells after transplantation if a problem were to arise46.  
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Other challenges to overcome 
Eventually, with a greater understanding of the development of enteric 
neural subtypes at all levels of GI tract development, reliable induction 
of ENCC-specific differentiation will be possible with iPSC lines. A non-
integrating viral transduction system to iPSCs will further reduce the 
inter-line variability and allow for the patient specific defects to be more 
readily compared. The therapeutic potential of iPSCs is great, they are 
arguably the most valuable tool for personalised regenerative medicine, 
but for their full potential to be realised it will be necessary to recognise 
and correct for their disadvantages. 
As the gut receiving transplantation has developed without ganglia the 
ECM and cellular environment of the tissue may be less receptive to ENS 
cell transplantation. As mentioned above, the creation of a suitable 
transplant agent or cell scaffold system may create a more receptive 
environment for the transplanted cells33,47. It is yet to be established if 
cytotoxicity from inflammation or fibrotic regions of scar formation at 
the anastomotic region in HSCR could make tissues less permissive to 
cell transplant invasion. In spinal cord injury the fibrotic tissue is known 
to be an issue for transplantation and scar ablation is common prior 
administration of cells48. 
Multi-disciplinary Treatment for HSC 
Current standards of care for HSCR patients leave many with poor anal 
sphincter control4,49, and this has been highlighted as a target region for 
initial cell therapy50. Given the safety and other challenges with the use 
of cell therapy that are yet to be overcome, such an approach is unlikely 
to reach the clinic for a number of years, and could have variable success 
rates within patients. In chapter 6, we introduce a novel treatment 
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possibility with the description of a device that could mimic the 
physiological function of the anal sphincter. In HSCR patients the 
constriction of the sphincter can lead to chronic constipation, and the 
damage to the musculature from surgery can lead to continued 
incontinence and anal leakage. There is need for a solution to allow for 
sphincter control for both opening and closing. Current solutions for 
this problem focus on closure, with no solution that will address both 
contraction and relaxation of the muscles51.  
The anal sphincter complex is comprised of the internal anal sphincter 
(IAS) and the external anal sphincter (EAS). It is the combined function 
of these sphincters that allows normal physiological defecation52. 
Function of the IAS is entirely involuntary and controlled by 
parasympathetic nerve fibres and the myenteric plexus whereas the EAS 
is mainly innervated by the pudendal nerve and is under voluntary 
control53. During defecation the increased pressure and stretch from 
bowel contents on the internal sphincter signals for it to relax, which is 
picked up by sensory nerves more distally and by the EAS. The pressure 
is sensed and these combined signals let us know that we need to 
defecate. The voluntary control of the EAS allows us to choose when to 
defecate. The lack of this control is the primary cause of adult faecal 
incontinence, and a number of pathologies can contribute to this54. The 
proposed solution of an electronic prosthetic anal sphincter is a multi-
disciplinary approach, combining surgical techniques with 
microelectronics and physiological function in order to provide patients 
with a modern and convenient solution to anatomical malfunction.  
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Conclusions 
HSCR development is complex and multifaceted. Although the 
overarching RET pathway can account for much of HSCR 
pathophysiology, there remains much to be learned from genetic 
studies. Collection of patient material and inclusion of parents and other 
family members in sequencing and functional cell-based research 
approaches will be instrumental in discovering new candidate genes 
and pathways that contribute to HSCR aetiology. The advancing of 
technologies to reliably sequence small amounts of DNA, and 
identification of methylation and other epigenetic marks will help to 
answer many questions that remain concerning the missing heritability 
observed in familial and sporadic HSCR cases. This, together with the 
understanding of HSCR as a variable symptom in multi-feature and 
syndromic cases, will enable more informative genetic counselling to 
patients and their families.  
Treatment options for HSCR have been stagnant for the past decades, 
and ongoing research is necessary before novel cell therapy approaches 
can be applied in a clinical setting. The differentiation of PSCs to 
appropriate lineages is progressing quickly and, given a concerted effort 
in safety and efficacy trials, clinical application is approaching. A further 
possible option that may be suitable to more patients is the use of an 
electronic prosthetic that could mimic anatomical function. In the future 
this could be used in combination with cell transplantation therapy and 
allow for the training of surrounding tissue and conditioning of 
transplanted cells to function within the anal sphincter complex. 
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Summary 
Hirschsprung disease (HSCR) is a disease of the intestines. It is 
characterised by an absence of the enteric nervous system (ENS) in a 
distal portion of the colon causing a contraction of the muscles and a 
functional obstruction. This results from defects in the differentiation, 
proliferation, migration and/or survival of ENS progenitors during 
development. HSCR can be an isolated trait or be part of a multi-feature 
syndrome. There are multiple developmental pathways which 
contribute to these defects and the genetic background of HSCR is 
complex, ~70% of cases cannot be explained by known genes. 
The possibilities of somatic variations contributing to the development 
of, and accounting for the missing heritability in, HSCR are discussed in 
chapters 2.1 and 2.2. In chapter 2.1 we outline the need for appropriate 
distinction between inherited parental mosaicism and true somatic 
mosaicism, proposing an experimental design to differentiate between 
the two in HSCR patient tissue. In chapter 2.2 this experimental design 
is utilised to look for ENCC specific variation in patient tissue. Although 
somatic variants were present in all included patients, somatic variants 
in HSCR related genes were not. Due to the nature of ENS development 
it is likely that somatic variants could not be identified in the distal colon. 
If damaging somatic variants were to occur in ENCCs, these cells would 
likely be out-competed to ENS niches before reaching these distal 
regions. 
In syndromic cases, HSCR can be a variable feature, the presence of 
common RET variants as well as the type of causative variant may 
influence HSCR development. The presence of HSCR in cases of 
Goldberg-Shprintzen syndrome (GOSHS) is discussed in chapter 3. 
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Pathogenic variations in KIF1 binding protein (KIF1BP) lead to GOSHS. 
A number of patients have been reported in the literature and 
truncating variations in KIF1BP have been found to be causative in all 
sequenced cases. We report nine new patients with KIF1BP variations, 
and functionally investigate three new missense variants which were 
suspected to be pathogenic in two patients with differing phenotypes. 
The three missense variants were found to result in a decrease in KIF1BP 
expression. The variant resulting in the lowest expression was present 
in the patient with the classical GOSHS and HSCR. Common 
predisposing HSCR SNPs were not found to have correlation with the 
presence or absence of HSCR in GOSHS patients. 
Another possible genetic factor for HSCR in syndromic cases is the 
presence of copy number variations (CNVs) that affect dosage sensitive 
HSCR loci. In chapter 4 we compare the size and number of CNVs 
between syndromic and non-syndromic cases of HSCR to find new 
candidate genes/loci. Syndromic HSCR patients with an unknown 
genetic aetiology have more and larger CNVs than isolated HSCR cases 
with a known pathogenic variant. These large CNVs overlap with dose-
sensitive genes which may help to identify candidate genes for HSCR. 
To further look into the underlying pathogenesis of HSCR development 
we created iPSC lines from four patients with different pathogenic 
variations. These cells offer possibilities for disease modelling, 
functional investigation of variants as well opening the door to future 
iPSC-enteric neuron transplantation options. In chapter 5 we present 
the characterisation of these patient-derived iPSCs and explore 
variations in their function compared to iPSCs generated from healthy 
controls. Three out of four of the patient-derived lines differentiated 
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effectively towards a vagal neural crest lineage and expressed 
appropriate markers. The less successful line also showed a markedly 
higher proliferation rate suggesting immaturity in differentiation. High 
seeding density was an important factor in successful differentiation, 
implicating cell-cell contact as vital for neural crest formation. Together 
our data suggest that for many HSCR patients, gene correction may not 
be necessary before transplantation trials. 
In order to bring an expedient option for the treatment of HSCR patients 
who continue to suffer from gastrointestinal problems following the 
current surgical standard of care, we may have to think beyond 
biological interventions. The technological world has arguably been 
able to advance at a faster rate than the development of purely 
biological treatment options. With the advances in microelectronics and 
prosthetic technologies incorporating sensory input, the opportunities 
for developing transplantable devices may be provide a more elegant 
solution than the more primitive prostheses currently available. These 
ideas are discussed in chapter 6, together with a patent proposal for an 
artificial prosthetic sphincter with an anatomically relevant mechanism 
and design which could provide therapeutic options for HSCR patients 
and others suffering from faecal incontinence or loss of anal sphincter 
control. 
In conclusion, the work of this thesis investigates the development of, 
and treatment options for, HSCR. We explore the missing heritability 
that is seen in HSCR, modes of development and differentiation of the 
progenitors of the ENS, suitability of various cell sources for 
transplantation therapy, and explore other possible treatment avenues 
for current and future HSCR patients. 
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Samenvatting 
De ziekte van Hirschsprung (HSCR) is een aangeboren neurologische 
aandoening van het maagdarmkanaal. De ziekte wordt gekenmerkt 
door de afwezigheid van ganglia in het uiteinde van de darm. Ganglia 
zijn groepjes zenuwcellen en gliacellen die behoren tot het enterische 
zenuwstelsel (engels: ENS). Daar waar de ganglia ontbreken trekken de 
spieren samen en veroorzaken zo een verstopping. Het ontbreken van 
ganglia kan het gevolg zijn van fouten in de differentiatie, proliferatie, 
migratie en/of overleving van ENS voorlopercellen tijdens hun 
ontwikkeling. De aanleg / ontwikkeling van het enterische zenuwstelsel 
is complex en dat kan meestal ook gezegd worden van het ontstaan van 
HSCR. De belangrijkste oorzaak voor het ontstaan van HSCR zijn fouten 
(mutaties) in het erfelijk materiaal. Er is één gen dat het meest 
gemuteerd voorkomt en dat is het RET-gen. We vinden mutaties van 
het RET-gen die genoeg veranderingen kunnen veroorzaken om de 
ziekte doen ontstaan, maar, veel vaker vinden we ook variaties die de 
kans op de ziekte verhogen, maar niet veroorzaken. Echter, in ~70% van 
de gevallen kan de volledige oorzaak nog niet worden verklaard door 
mutaties. 
HSCR kan als een op zichzelf staande ziekte voorkomen, maar kan ook 
in combinatie met andere afwijkingen worden gediagnosticeerd; dan 
noemen we het een syndroom.  
Zoals gezegd is de oorzaak van de ziekte veelal erfelijk, en mutaties in 
een groot aantal genen zijn al gevonden. Deze mutaties erft de patiënt 
vaak over van één van de ouders. Soms ontstaan de mutaties in de 
geslachtscellen (dit noemen we ook wel kiembaan mozaïcisme) en heeft 
alleen het kind de genetische afwijking. Maar zelfs als we alle genen 
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screenen vinden we niet altijd een duidelijke verklaring. Een hypothese 
die we hebben onderzocht was of er mutaties voorkomen alleen in het 
ENS. Die mutaties moeten dan tijdens de ontwikkeling van het kind 
ontstaan. We noemen dergelijke mutaties somatische mutaties of 
variaties. Deze hypothese, dat somatische varianten bijdragen aan de 
ontwikkeling van HSCR, wordt besproken in de hoofdstukken 2.1 en 2.2. 
In hoofdstuk 2.1 schetsen we de noodzaak voor een duidelijk 
onderscheid tussen kiembaan mozaïcisme en werkelijk somatisch 
mozaïcisme, en stellen we een toepasbaar experimenteel plan voor om 
in weefsel van HSCR patiënten dit onderscheid ook daadwerkelijk te 
kunnen maken. In hoofdstuk 2.2 wordt van dit experimentele plan 
gebruik gemaakt om te onderzoeken of er in het ENS van patiënten 
inderdaad sprake is van specifieke somatische variaties in de 
zenuwcellen. Alhoewel somatische varianten aanwezig waren in alle 
onderzochte patiënten, vonden we er geen in de genen waarvan bekend 
was dat ze HSCR kunnen veroorzaken. Ook beschrijven we dat, gezien 
de manier waarop het ENS wordt aangelegd, de kans op het vinden van 
somatische varianten niet heel waarschijnlijk is; we denken namelijk dat 
als somatische varianten zouden voorkomen in het ENS, deze cellen 
vermoedelijk weg zouden worden geconcurreerd door gezonde ENS 
specifieke cellen voordat ze deze plek bereiken. 
Zoals gezegd, kan HSCR onderdeel zijn van een syndroom. Eén van de 
bekende syndromen is Goldberg-Shprintzen syndroom (GOSHS). We 
bespreken dit syndroom in hoofdstuk 3. Pathogene varianten in het KIF1 
bindingseiwit (KIF1BP) veroorzaken GOSHS, met HSCR als een variabel 
kenmerk. Alhoewel HSCR geen criterium is voor de diagnose GOSHS, 
zijn er mogelijk wel factoren die er voor zorgen dat deze patiënten HSCR 
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ontwikkelen. Een aantal patiënten zijn beschreven in de literatuur en in 
al die patiënten waarbij DNA geanalyseerd werd, werden varianten 
gevonden die een verkort KIF1BP eiwit tot gevolg hebben. We 
beschrijven negen nieuwe patiënten met varianten in KIF1BP. Ook 
hebben we functioneel onderzoek gedaan naar drie nieuwe missense 
varianten (missense: vervanging van een aminozuur door een ander 
aminozuur), t.w. varianten waarvan we denken dat ze ziektes kunnen 
veroorzaken. We hebben deze varianten gevonden in twee patiënten 
met verschillende fenotypes. De drie missense varianten bleken een 
verlaagde KIF1BP expressie tot gevolg te hebben. De variant met de 
laagste expressie werd gevonden in de patiënt met klassiek GOSHS en 
HSCR. We hebben geen veelvoorkomende veranderingen gevonden die 
gecorreleerd zijn aan de aan- of afwezigheid van HSCR in GOSHS 
patiënten. 
Een andere mogelijk genetische factor voor HSCR in syndromale 
gevallen, is de aanwezigheid van grote variaties in het DNA, d.w.z. grote 
stukken van een chromosoom die extra of juist minder aanwezig zijn. In 
hoofdstuk 4 vergelijken we de grootte en het aantal 
chromosoomafwijkingen (CNVs) tussen syndromale en niet-syndromale 
HSCR patiënten om nieuwe kandidaat genen/loci te vinden. Syndromale 
HSCR patiënten met een onbekende genetische oorzaak hebben meer 
en grotere CNVs dan patiënten met alleen HSCR en een bekende 
ziekteverwekkende mutatie. Deze grote CNVs overlappen met dosis-
gevoelige genen. Deze bevindingen kunnen helpen bij het identificeren 
van nieuwe kandidaat genen voor HSCR.  
Om de onderliggende pathogenese van HSCR verder te onderzoeken, 
hebben we cellijnen gemaakt van geïnduceerde pluripotente stamcellen 
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(engels: iPSCs) van vier patiënten met mutaties in verschillende genen. 
Deze cellen bieden de mogelijkheid om het ziektebeeld te modelleren 
en de varianten functioneel te onderzoeken. Dit type onderzoek opent 
de deur naar toekomstige therapie. We denken dat daar waar de 
neuronen ontbreken deze cellen mogelijk gebruikt kunnen worden voor 
transplantatie in de darm. In hoofdstuk 5 laten we de karakterisering, 
van deze van de patiënt afgeleide cellijnen zien. Ook gaan we na of de 
variaties die we hebben gevonden effect hebben op de cellijnen (we 
vergelijken de patiënten cellijnen met controle cellijnen). Drie van de 
vier van de patiënt afgeleide lijnen lieten geen echte verschillen zien. 
Eén cellijn was anders. De cellijn vermeerderde zich aanmerkelijk sneller 
dan de rest, hetgeen duidt op een onrijpe differentiatie. Een belangrijke 
factor voor het goed groeien is een hoge celdichtheid bij het opgroeien, 
wat er op duidt dat cel-cel contact van vitaal belang is bij de vorming 
van deze cellen. Omdat de meeste cellen geen groot verschil lieten zien 
lijkt het erop dat deze cellijnen geschikt zouden moeten zijn voor 
therapie. 
Om met een doeltreffend alternatief te komen voor de behandeling van 
HSCR patiënten die last blijven houden van gastro-intestinale 
problemen na de huidige standaard operatieve behandeling, moeten 
we verder denken dan de biologische interventies. In de technische 
wereld is de vooruitgang sneller gegaan dan de ontwikkeling op het 
gebied van puur biologische behandelmogelijkheden. Met name de 
vooruitgang in de micro-elektronica en de prothetische technologieën 
die gevoelssensoren weten in te bouwen, bieden mogelijkheden om 
transplanteerbare hulpmiddelen te ontwikkelen. Deze ideeën worden 
besproken in hoofdstuk 6, samen met een patent protocol voor een 
kunstmatige sluitspierprothese met een anatomisch toepasbaar 
Hirschsprung Disease: Development & Treatment Avenues
282
mechanisme en ontwerp. Deze zou kunnen voorzien in therapeutische 
behandelmogelijkheden voor HSCR en andere patiënten die leiden 
onder fecale incontinentie of het gebrek aan controle over de sluitspier. 
Samengevat, het werk gepresenteerd in dit proefschrift, onderzoekt de 
ontwikkeling van, en de behandelmogelijkheden voor, HSCR. We 
hebben gezocht naar erfelijke factoren in HSCR, de wijze van 
ontwikkeling en differentiatie van de ENS voorlopercellen, de 
geschiktheid van cellen met verschillende origine voor transplantatie 
therapieën én andere behandelmogelijkheden voor huidige en 
toekomstige HSCR patiënten.  
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